ClinicalTrials.gg
Active, not recruitingNCT06335979Updated Jun 30, 2026

An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).

A Phase 1 interventional study of PIT565 in Systemic Lupus Erythematosus, SLE, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 11 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 14 studies in Lupus Erythematosus, Systemic by Novartis — 2 open to participants now, 8 under way, 4 of them phase 3. Lupus Erythematosus, Systemic · Novartis.

Planned enrollment
11th of 14
54 · median 131
Started
2024
with 4 others
Phase 1
4 of 14
1 open now
Registered
11th of 14
by date

Among the 14 studies in Lupus Erythematosus, Systemic by Novartis, this one is the 11th largest by planned enrollment, is one of 5 that started in 2024, is one of 4 in phase 1, and was the 11th registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

2 of the 14 studies in Lupus Erythematosus, Systemic by Novartis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Lupus Erythematosus, Systemic by Novartis, or all of them as a file.
02

Study summary

The purpose of the study is to determine the safety, tolerability, and pharmacokinetics of PIT565 in participants with SLE

Read the detailed description

This is an open-label, ascending dose, uncontrolled study in participants with SLE systemic lupus erythematosus (SLE). PIT565 will be administered subcutaneously (s.c.) following premedication.

Up to 8 cohorts are planned. Every cohort will start with 3 sentinel participants and, depending on safety as well as observed biological activity, may have additional optional participants. The decision to escalate the dose from one cohort to the next will be based both on safety and PD data. After the identification of a dose level that has been declared safe and has induced predefined B cell depletion in 100% of the participants (candidate dose level), the cohort from this candidate dose level can be expanded with up to 12 additional participants (up to a total of 15 participants per cohort).

03

Conditions studied

  • Systemic Lupus Erythematosus, SLE

Keywords

  • Systemic lupus erythematosus
  • SLE
  • ascending dose
  • B cells
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of SLE according to the 2019 ACR/EULAR criteria
  • Documentation of SLE autoantibodies
  • Active SLE disease, as demonstrated by a SLEDAI-2K ≥ 4 at screening
  • Failure to respond to standard-of-care medicines for the treatment of SLE as detailed in the protocol
  • Immunization against pneumococcus, meningococcus, influenza, and COVID-19

Exclusion criteria

Exclusion Criteria:

  • Severe SLE-related organ damage dysfunction or life-threatening disease at screening.
  • Any acute, severe lupus-related flare during screening that needs immediate treatment such as acute CNS lupus (e.g., psychosis, epilepsy) or catastrophic antiphospholipid syndrome.
  • Presence of severe lupus kidney disease as defined by worsening proteinuria or estimated (eGFR) which in the opinion of the Investigator requires induction or maintenance treatment at screening.
  • History or current diagnosis of or cardiac abnormalities indicating a significant risk of safety for participants.
  • Use of prohibited medication defined in the protocol.
  • active, opportunistic, chronic or recurrent infection (including, , , ) confirmed one month prior to or during screening.
  • Serious medical illness likely to interfere with participation in this clinical study.
  • Women of , defined as all women physiologically capable of becoming pregnant from menarche until becoming , unless they are using highly effective methods of

Other protocol defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Dose level 1

    Drug: PIT565

  • Experimental
    Cohort 2

    Dose level 2

    Drug: PIT565

  • Experimental
    Cohort 3

    Dose level 3

    Drug: PIT565

  • Experimental
    Cohort 4

    Dose level 4

    Drug: PIT565

  • Experimental
    Cohort 5

    Dose level 5

    Drug: PIT565

  • Experimental
    Cohort 6

    Dose level 6

    Drug: PIT565

  • Experimental
    Cohort 7

    Dose level 7

    Drug: PIT565

  • Experimental
    Cohort 8

    Dose level 8

    Drug: PIT565

Interventions

  • DrugPIT565

    In each cohort, there will be 3 sentinel participants. Additional participants might be added depending on safety and observed biological activity.

06

What researchers measure

Primary outcomes

  1. Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs)

    Safety assessments of PIT565 including changes in vital signs, electrocardiograms (ECG) and laboratory results from baseline

    Time frame: From Study Day 1 until Study Day 180

Secondary outcomes

  1. Maximum Observed Blood Concentrations (Cmax)

    Cmax is the maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (mass x volume-1).

    Time frame: From pre-dose Day 1 until Day 29

  2. Presence/absence of Anti-drug Antibodies

    Assess immunogenicity of PIT565 at pre-dose, and over time

    Time frame: From pre-dose Day 1 until Day 180

07

Study locations

11 sites
  • Novartis Investigative Site
    Beijing, 100191, China
  • Novartis Investigative Site
    Beijing, 100730, China
  • Novartis Investigative Site
    Berlin, 10117, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Budapest, H-1083, Hungary
  • Novartis Investigative Site
    Szeged, 6725, Hungary
  • Novartis Investigative Site
    Leiden, South Holland 2333 CL, Netherlands
  • Novartis Investigative Site
    Santiago Compostela, A Coruna 15706, Spain
  • Novartis Investigative Site
    Barcelona, 08035, Spain
  • Novartis Investigative Site
    Madrid, 28034, Spain
  • Novartis Investigative Site
    Bern, 3010, Switzerland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Nov 2027, 37 months after the start.

Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's planned 37 months is above that.

Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2024
First posted
Mar 28, 2024
StartActual
Oct 8, 2024
Primary completionEst.
Nov 17, 2027
CompletionEst.
Nov 17, 2027
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06335979
Responsible party
Sponsor
First posted
Mar 28, 2024
Start date
Oct 8, 2024
Primary completion
Nov 17, 2027 (estimated)
Completion
Nov 17, 2027 (estimated)
Last update
Jun 30, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565

Start the discussion